Gilbert & Rose-Marie Chagoury School of Medicine, LAU, Byblos, Lebanon, P.O. Box 36.
Gilbert & Rose-Marie Chagoury School of Medicine, LAU, Byblos, Lebanon, P.O. Box 36.
Eur J Pharmacol. 2024 Aug 15;977:176719. doi: 10.1016/j.ejphar.2024.176719. Epub 2024 Jun 6.
Mesenchymal stem cells (MSCs) are multipotent stem cells that are able to differentiate into multiple lineages including bone, cartilage, muscle and fat. They hold immunomodulatory properties and therapeutic ability to treat multiple diseases, including autoimmune and chronic degenerative diseases. In this article, we reviewed the different biological properties, applications and clinical trials of MSCs. Also, we discussed the basics of manufacturing conditions, quality control, and challenges facing MSCs in the clinical setting.
Extensive review of the literature was conducted through the databases PubMed, Google Scholar, and Cochrane. Papers published since 2015 and covering the clinical applications and research of MSC therapy were considered. Furthermore, older papers were considered when referring to pioneering studies in the field.
The most widely studied stem cells in cell therapy and tissue repair are bone marrow-derived mesenchymal stem cells. Adipose tissue-derived stem cells became more common and to a lesser extent other stem cell sources e.g., foreskin derived MSCs. MSCs therapy were also studied in the setting of COVID-19 infections, ischemic strokes, autoimmune diseases, tumor development and graft rejection. Multiple obstacles, still face the standardization and optimization of MSC therapy such as the survival and the immunophenotype and the efficiency of transplanted cells. MSCs used in clinical settings displayed heterogeneity in their function despite their extraction from healthy donors and expression of similar surface markers.
Mesenchymal stem cells offer a rising therapeutic promise in various diseases. However, their potential use in clinical applications requires further investigation.
间充质干细胞(MSCs)是多能干细胞,能够分化为多种谱系,包括骨、软骨、肌肉和脂肪。它们具有免疫调节特性和治疗多种疾病的能力,包括自身免疫和慢性退行性疾病。在本文中,我们回顾了 MSCs 的不同生物学特性、应用和临床试验。此外,我们还讨论了制造条件、质量控制的基础,以及 MSCs 在临床环境中面临的挑战。
通过 PubMed、Google Scholar 和 Cochrane 数据库进行了广泛的文献综述。考虑了自 2015 年以来发表的涵盖 MSC 治疗临床应用和研究的论文,并且在提到该领域的开创性研究时,也考虑了较旧的论文。
在细胞治疗和组织修复中研究最多的干细胞是骨髓来源的间充质干细胞。脂肪组织来源的干细胞变得更加普遍,而其他干细胞来源(例如,包皮来源的 MSC)则较少。MSC 疗法也在 COVID-19 感染、缺血性中风、自身免疫性疾病、肿瘤发展和移植物排斥等情况下进行了研究。尽管从健康供体中提取并表达相似的表面标记物,但 MSC 疗法的标准化和优化仍然面临许多障碍,例如移植细胞的存活率、免疫表型和效率。在临床环境中使用的 MSCs 尽管从健康供体中提取并表达相似的表面标记物,但它们的功能仍存在异质性。
间充质干细胞在各种疾病中提供了有希望的治疗方法。然而,它们在临床应用中的潜在用途需要进一步研究。